BioAgilytix
  • Twitter
  • LinkedIn
  • Youtube
  • Careers
  • Blog
  • Contact
  • Services
    • Our Capabilities
    • Assay Focus
      • Biomarkers
      • Immunogenicity
        • Anti-drug Antibody (ADA) Assays
        • Neutralizing Antibody (NAb) Assays
      • Pharmacokinetics (PK)
      • Cell-Based Assays
      • Critical Reagents
      • Toxicology Studies
    • BioAgilytix Diagnostics
    • Biomarker Menu
    • Disease State Expertise
      • Oncology
      • Metabolic
      • Autoimmune
      • Neurology
    • Industries Served
      • Pharma & Biotech
      • Agricultural Biotechnology
    • Our Quality Commitment
    • Management Processes
      • Project Management
      • Sample Management
      • Data Management
  • Solutions
    • COVID-19 Testing for Clinical Trials
    • COVID-19 Workforce Testing
    • Gene Therapy
      • Modified & Novel Vehicles for Gene Therapies
    • CAR T-Cell Therapy
    • Vaccines
    • Biosimilars
    • Antibody Drug Conjugates (ADCs)
    • Immuno-oncology
  • Technology
    • Our Platforms
      • ELISA
      • MSD-ECL
      • Flow Cytometry
      • Quantitative Real-Time PCR (qPCR)
      • Roche cobas Analyzer
      • Gyrolab
      • Ella
      • LI-COR Odyssey
      • Luminex
      • Biacore
      • ImmunoCAP
      • ELISpot
    • Automation
  • Team
    • Leadership Team
    • Experts
  • Company
    • About Us
    • The BioAgilytix Way
    • USA Headquarters
    • European Headquarters
      • French Research Tax Credit (CIR) Accreditation
    • Boston Laboratory
    • Mission, Vision & Values
    • Meet Our Partners
    • Awards
    • Careers
  • Resources
    • Resource Center
    • Gene & Cell Therapy Center
    • Our Blog
    • Case Studies
    • Testimonials
  • News
    • Recent News
    • BioAgilytix in the News
    • Events
  • Careers
    • Careers at BioAgilytix
From The Stage
← Back to From The Stage
Posted by Ad Leverage October 2, 2018

Fast 50 (#24)

Fast 50 (#24)
Share This

Subscribe for Updates

Follow BioAgilytix

Popular Posts

Applying Cell-Based Assays, Part 1: Neutralizing Antibody (NAb) Detection

Protein-based biologic agents have the potential to induce…

Read More

Exploratory Biomarker Testing: to Qualify or Validate the Assay?

There is a lot of confusion in the…

Read More

The Importance of Parallelism in Biomarker Assay Development

Parallelism is a vitally important factor in clinical…

Read More
Lab experts working - Considerations to Set ADA Cut Points

Considerations to Set ADA Cut Points

Cut points are the threshold values for the…

Read More
BioAgilytix whitepaper on desk

New FDA Guidance on Developing and Validating Assays for ADA Detection: Key Updates and Clarifications

The FDA’s recently released new guidance, designed to facilitate development and validation of assays for the detection of anti-drug antibodies for immunogenicity testing, includes several needed revisions and clarifications. Our own immunogenicity expert, Dr. Arno Kromminga, outlines the significant updates made.

Read More

Select a Category

  • CRO Selection
  • Biomarkers
  • Bioanalytical Lab Quality
  • BioAgilytix Insight

Recent Insights

Researcher adding samples to a 96 well plate

Todd Lester

Analytical Assays Determine Biosimilar Product Quality

Read the article

BioAgilytix

  • Twitter
  • LinkedIn
  • Facebook
USA Headquarters
2300 Englert Dr
Durham, NC, 27713
919-381-6097
 
European Headquarters
Lademannbogen 10
22339 Hamburg Germany
+49 40 526779 0
 
Boston Laboratory
1320 Soldiers Field Road
Boston, MA, 02135
617-456-0700
 
http://www.bioagilytix.com [email protected]

Services

  • Biomarkers
  • Immunogenicity
  • Pharmacokinetics (PK)
  • Cell-Based Assays
  • Gene Therapy
  • CAR T-Cell Therapy
  • Biosimilars
  • Antibody Drug Conjugates (ADCs)
  • Immuno-oncology

Platforms

  • ELISA
  • MSD-ECL
  • Flow Cytometry
  • Quantitative Real-Time PCR (qPCR)
  • Roche cobas Analyzer
  • Gyrolab
  • Ella
  • LI-COR Odyssey
  • Luminex
  • Biacore
  • ImmunoCAP
  • ELISpot

Subscribe to Our Newsletter

Copyright © 2020 BioAgilytix Labs. All rights reserved.

  • Terms of Use
  • Privacy Notice